Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables

Ahmed Abuabdou, Eric R. Rosenbaum, Saad Zafar Usmani, Bart Barlogie, Michele Cottler-Fox

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Mobilization regimens for CD34+ cells have generally been judged successful based on the number of cells collected without evaluating mobilization separately from collection. Using retrospective data for patients who collected CD34+ cells on Total Therapy protocols 3a/3b (VTD-PACE) and Total Therapy 4/5 using a novel regimen that added low dose melphalan to VTD-PACE (MVTD-PACE), we analyzed mobilization and collection variables separately. A significant difference favoring MVDT-PACE was found in mean CD34+ cells/μL on day 2 of collection and in mean ratio of CD34+ cells/μL on day 2 to day 1. However, because apheresis variables and growth factor dose during collection were manipulated to optimize individual collections, the two regimens were not significantly different when the mean total CD34+ cells ×106/kg collected was compared. Thus, when evaluating a emotherapy regimen or new growth factor for mobilization, it is important to realize that total CD34+ cells collected is dependent on both mobilization and collection variables.

Original languageEnglish
Pages (from-to)251-255
Number of pages5
JournalJournal of Clinical Apheresis
Volume29
Issue number5
DOIs
StatePublished - 1 Oct 2014
Externally publishedYes

Keywords

  • Apheresis
  • CD34+
  • Melphalan
  • Mobilization
  • Myeloma

Fingerprint

Dive into the research topics of 'Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables'. Together they form a unique fingerprint.

Cite this